Filing Season Finds: Tuesday, March 6 – Specialty pharmacy red flag

For March 5, 2018, our forensic accounting red flag comes from a specialty pharmacy company with rising supplier concentration.

 

KeithJJ / Pixabay

We pulled this highlight from yesterday’s research of 133 10-K filings, from which our Robo-Analyst technology collected 20,292 data points. Our analyst team used this data to make 3,309 forensic accounting adjustments with a dollar value of $434 billion. The adjustments were applied as follows:

  • 1,415 income statement adjustments with a total value of $38 billion
  • 1,370 balance sheet adjustments with a total value of $167 billion
  • 524 valuation adjustments with a total value of $228 billion

Figure 1: Filing Season Diligence for Monday, March 5th

Sources: New Constructs, LLC and company filings. 

We believe this research is necessary to fulfill the Fiduciary Duty of Care. Ernst & Young’s recent white paper, “Getting ROIC Right”, demonstrates how these adjustments contribute to meaningfully superior models and metrics.

Today’s Forensic Accounting Needle in a Haystack Is for Healthcare Investors

Analyst Lindsay Bohannon found an unusual item yesterday in Diplomat Pharmacy’s (DPLO) 10-K.

On page 70, DPLO disclosed that the percentage of its cost of goods sold attributable to its second and third largest suppliers, Celgene (CELG) and Pharmacyclics (ABBV) had risen from 21% in 2015 to 31% last year. Crucially, the company states that the drugs it purchases from these two companies “are not available from any other source.”

The increased concentration for CELG and ABBV comes at the expense of DPLO’s top supplier, AmerisourceBergen (ABC), which saw its share of cost of goods sold decline from 50% in 2015 to 41% last year. Unlike the other two suppliers, DPLO does have alternative vendors available for the drugs it purchases from ABC.

DPLO’s increased reliance on CELG and ABBV decreases its negotiating leverage and puts heightened pressure on already narrow margins. Since 2015, DPLO’s after-tax profit (NOPAT) margins have declined by more than half, from 1% to 0.4%. Its return on invested capital (ROIC), has fallen from 6% to 2%. This decline in profitability has multiple causes, but decreased leverage versus suppliers certainly seems to be a contributing factor.

This article originally published on March 6, 2018.

Disclosure: David Trainer, Lindsay Bohannon, and Sam McBride receive no compensation to write about any specific stock, sector, style, or theme.

Follow us on Twitter (#filingseasonfinds), Facebook, LinkedIn, and StockTwits for real-time alerts on all our research.

LEAVE A COMMENT


X
Saved Articles
X
TextTExtLInkTextTExtLInk

The Life and Career of Charlie Munger

Charlie is more than just Warren Buffett’s friend and Berkshire Hathaway’s Vice Chairman – Buffett has actually credited him with redefining how he looks at investing. Now you can learn from Charlie firsthand via this incredible ebook and over a dozen other famous investor studies by signing up below:

  • Learn from the best and forever change your investing perspective
  • One incredible tidbit of knowledge after another in the page-turning masterpiece of a book
  • Discover the secrets to Charlie’s success and how to apply it to your investing
Never Miss A Story!
Subscribe to ValueWalk Newsletter. We respect your privacy.

Are you an intelligent investor?

ValueWalkPremium is a website and newsletter for smart investors like yourself. We focus on the latest hedge fund industry news much of which is not in the public domain and obtained via our sources.

We also have 10 years of resources on how to use this information to better your investment process.

Sign up for  today for only a few dollars a day and get a 3 day no obligation trial with a targeted 20% discount coupon code.

Cancel anytime during trial and you are never charged.

Limited time offer: For first 50 subscribers

0